What are analysts'target prices for Insys Therapeutics'stock?
4 Wall Street analysts have issued 12 month target prices for Insys Therapeutics' shares. Their forecasts range from $4.00 to $11.00. On average, they expect Insys Therapeutics' stock price to reach $6.60 in the next year. View Analyst Price Targets for Insys Therapeutics.
What is Insys Therapeutics's return on equity?
INSYS Therapeutics had a negative trailing twelve-month return on equity of 1,430.37% and a negative net margin of 346.61%. INSYS Therapeutics's revenue was down 68.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.19) earnings per share. View INSYS Therapeutics' earnings history.
What is the ticker symbol for Insys Therapeutics?
INSYS Therapeutics trades on the NASDAQ under the ticker symbol "INSY." How much money does INSYS Therapeutics make? INSYS Therapeutics has a market capitalization of $0.00 and generates $82.08 million in revenue each year.
When did Insys Therapeutics stock split in 2014?
INSYS Therapeutics's stock split on the morning of Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were payable to shareholders after the market closes on Friday, March 28th 2014.
What happened to INSY stock?
The Insys Therapeutics bankruptcy news coming out on Monday has INSY stock tanking hard. Insys Therapeutics (NASDAQ:INSY) says that it has filed for Chapter 11 bankruptcy protection. The company will be using this time to sell off assets of its business in an effort to cover legacy legal liabilities.
Is Eliem Therapeutics a buy?
Eliem Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Is pliant Therapeutics a buy?
Pliant Therapeutics Inc (NASDAQ:PLRX) The 7 analysts offering 12-month price forecasts for Pliant Therapeutics Inc have a median target of 40.00, with a high estimate of 51.00 and a low estimate of 27.00. The median estimate represents a +111.64% increase from the last price of 18.90.
Is PLRX a good stock to Buy?
The consensus among 4 Wall Street analysts covering (NASDAQ: PLRX) stock is to Strong Buy PLRX stock.
Is Stoke Therapeutics a buy?
Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
Insys Therapeutics, Inc. (INSY) Company Bio
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. The company was founded in 2002 and is based in Chandler, Arizona.